Parmax Pharma Limited has announced the re-appointment of Dr. Umang Gosalia as Managing Director for an extended five-year term. The Board of Directors approved this strategic leadership decision on May 02, 2026, following recommendations from the Nomination and Remuneration Committee.

Board Approval and Timeline

The company's Board meeting, held on May 02, 2026, formally approved Dr. Gosalia's re-appointment as Managing Director for a period of five years. The new term will commence on June 28, 2026, and continue until June 27, 2031. This re-appointment is contingent upon shareholder approval at the upcoming Annual General Meeting or Extra-ordinary General Meeting.

Leadership Profile

Dr. Umang Gosalia brings substantial expertise to his continued role as Managing Director. He holds a Ph.D. in Organic Chemistry and possesses over one and a half decades of experience in chemistry and various types of organic reactions. Currently, he oversees all production activities of the company and has been associated with Parmax Pharma since 2016.

Regulatory Compliance

The re-appointment has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided all required disclosures as mandated under Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Next Steps

The re-appointment will require formal approval from shareholders at the company's ensuing Annual General Meeting or Extra-ordinary General Meeting. This standard corporate governance procedure ensures transparency and shareholder participation in key leadership decisions. The company has notified the Bombay Stock Exchange Limited of this development as part of its regulatory disclosure obligations.

Parmax Pharma Limited has filed its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate confirms adherence to regulatory requirements for the dematerialization process during Q4 FY26.

Regulatory Compliance Certificate

The company submitted the mandatory certificate to BSE Limited on April 17, 2026, as required under the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. Managing Director Umang Gosalia (DIN: 05153830) digitally signed the certificate, confirming compliance with prescribed timelines and procedures.

The certificate validates that all securities received for dematerialization during the quarter were immediately mutilated and cancelled after due verification. The depository's name was substituted in the company's records as the registered owner within the prescribed timelines from receipt of the security certificate.

Registrar Confirmation

Purva Sharegistry (India) Pvt. Ltd., the company's Registrar and Share Transfer Agent (RTA), provided confirmation supporting the quarterly certificate. The RTA holds SEBI registration number INR000001112 as a Category 1 Registrar for IPO and Share Transfer services.

Compliance Officer Ms. Deepali Gaonkar from Purva Sharegistry confirmed that security certificates received for dematerialization were properly processed and that the securities are listed on stock exchanges where earlier issued securities are listed.

Dematerialization Details

The quarter witnessed dematerialization activity involving specific share certificates. The company processed dematerialization requests within the regulatory framework, ensuring proper documentation and timeline adherence.

The dematerialization involved two certificates of 100 shares each, both processed on January 23, 2026. Certificate number 0019483 covered distinctive numbers 3135301 to 3135400, while certificate number 0019484 covered distinctive numbers 3135401 to 3135500.

Compliance Framework

The quarterly certificate filing demonstrates the company's commitment to maintaining regulatory compliance under SEBI guidelines. The process ensures transparency in share transfer operations and maintains accurate records of ownership changes through the depository system.

The certification process involves coordination between the company, its RTA, and depositories to ensure seamless dematerialization while maintaining regulatory standards. This quarterly filing represents part of the ongoing compliance requirements for listed companies under SEBI regulations.